Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced plans to spin off its Consumer Health business, creating two independent companies. The split aims to enhance focus, agility, and innovation in healthcare, positioning the new Johnson & Johnson as a leader in pharmaceuticals and medical devices, projected to generate $77 billion in revenue for FY 2021. The New Consumer Health Company will be a global leader in health products with $15 billion projected revenue. The separation is expected to be tax-free for U.S. federal purposes and is targeted for completion within 18-24 months, pending regulatory approvals.
Johnson & Johnson (NYSE: JNJ) announced a partnership with the U.S. Government and Gavi to distribute its single-shot COVID-19 vaccine via the COVAX Humanitarian Buffer. This initiative aims to reach vulnerable populations in conflict zones and areas lacking government vaccination campaigns. The first vaccine deliveries are set for the coming days. The company plans to supply up to 900 million doses on a not-for-profit basis, highlighting its commitment to equitable global access in the fight against the pandemic.
Johnson & Johnson (NYSE: JNJ) has announced a $5 million endowment to Research!America to establish an annual award aimed at recognizing significant contributions to public health. This award will be part of the 26th annual Research!America Advocacy Awards Program. The initiative highlights leaders tackling key health issues like smoking cessation and COVID-19 collaboration. Notable awardees include Matthew Myers, Bill Novelli, and Vivian W. Pinn, MD, who have made significant impacts in public health. The company emphasizes its commitment to advancing global health.
On October 21, 2021, Johnson & Johnson (NYSE: JNJ) announced that the CDC's Advisory Committee on Immunization Practices recommended its COVID-19 vaccine as a booster for individuals who have received authorized COVID-19 vaccines. The vaccine demonstrated 94% protection against COVID-19 as a booster, emphasizing its durable protection. The recommendations include boosters for adults aged 18 and older who either received the single-shot Johnson & Johnson vaccine or completed primary vaccination with an mRNA vaccine at least six months earlier. The recommendation is pending review by the CDC and HHS.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the fourth quarter of 2021. This dividend will be paid on December 7, 2021, to shareholders recorded as of the close of business on November 23, 2021. The ex-dividend date is scheduled for November 22, 2021. With over 130 years in the healthcare industry, Johnson & Johnson remains committed to enhancing health and well-being globally.
Johnson & Johnson (NYSE: JNJ) received Emergency Use Authorization (EUA) from the FDA for its COVID-19 vaccine booster for adults aged 18 and older, effective two months after the initial vaccination. The booster dose will share the same formulation and dosage as the primary shot. The EUA is based on a favorable recommendation from the FDA's advisory committee, highlighting robust efficacy and safety data from clinical trials. Over 15.2 million doses of the vaccine have already been administered in the U.S., underscoring its significant role in combating the ongoing pandemic.
Johnson & Johnson (NYSE: JNJ) reported Q3 2021 results, showcasing a 10.7% increase in reported sales to $23.3 billion and a 3.2% rise in net earnings to $3.67 billion. Adjusted EPS surged 18.2% to $2.60. Pharmaceutical sales grew 13.8%, led by drugs like DARZALEX and STELARA. Medical Devices operations rose 7.6%, while Consumer Health increased 5.7%. CEO Alex Gorsky announced his transition to Joaquin Duato effective January 2022, underscoring ongoing investment in innovation amidst dynamic market conditions.
Johnson & Johnson (NYSE: JNJ) announced that the FDA's Vaccines Advisory Committee voted 19-0 in favor of Emergency Use Authorization (EUA) for a booster dose of its COVID-19 vaccine for adults at least two months post-initial vaccination. This decision is backed by results from the Phase 3 ENSEMBLE 2 trial showing 94% protection against symptomatic COVID-19 after two months and 100% against severe cases. The company's commitment to combat COVID-19 continues as it awaits further regulatory decisions both nationally and internationally.
On October 14, 2021, lawyers representing over 30,000 women filed lawsuits against Johnson & Johnson (JNJ) regarding cancer claims tied to its talc body powders. They criticize J&J's bankruptcy move to evade legal accountability as hypocritical and unjust, especially given the company's substantial profits. J&J’s new subsidiary, LTL Management LLC, has filed for bankruptcy to manage these claims, proposing a $2 billion settlement fund despite total liabilities estimated at over $25 billion. The legal battle raises concerns for pending trials and could prolong suffering for affected patients.
Johnson & Johnson (NYSE: JNJ) announced that LTL Management LLC, a newly formed subsidiary, has filed for voluntary Chapter 11 bankruptcy to manage claims related to cosmetic talc litigation. This bankruptcy aims to provide an equitable resolution for current and future claimants. JNJ will fund LTL with a $2 billion trust and royalty revenue streams worth over $350 million. The company maintains its stance on the safety of its talc products, citing favorable jury trial outcomes. All cosmetic talc litigation cases will be stayed pending the bankruptcy proceedings.